Marisa Wexler, MS, senior science writer —

Ofev (nintedanib) slows the rate of decline in lung function in people with interstitial lung diseases (ILDs) associated with autoimmune diseases, a new analysis of data from a Phase 3 clinical trial suggests. Ofev is an anti-fibrotic therapy — a medication that lessens tissue scarring — that is already…

The Pulmonary Fibrosis Foundation (PFF) announced a research initiative that aims to expand precision medicine strategies for diagnosing and treating idiopathic pulmonary fibrosis (IPF). The study, called PRECISIONS (for Prospective tReatment EffiCacy in IPF uSIng genOtype for Nac Selection), is being funded by a $22 million grant from the National Institutes of Health and …

Investigational therapy AD-214 raised no safety concerns in preliminary studies in non-human primates, and AdAlta, the therapy’s developer, is now planning to launch a Phase 1 clinical trial in humans, the company announced. AD-214 is a modification of AdAlta’s original lead candidate for the treatment of pulmonary fibrosis…

Activating a dopamine receptor on fibroblast cells (connective tissue cells) may help slow, or even reverse, fibrosis in mice, a study suggests. The study, “Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis,” was published in the journal Science Translational Medicine. Fibrosis — abnormal…

MN-001, a potential treatment for idiopathic pulmonary fibrosis (IPF), will soon have patent protections in China. MediciNova, the company developing MN-001 (tipelukast), received a Notice of Allowance from the Chinese Patent Office, which means that the company’s application fulfills all necessary requirements. Once issued, the patent is expected to…

Esbriet (pirfenidone) shows similar benefits for people with idiopathic pulmonary fibrosis (IPF) in real-world settings as it does in clinical trials, a new study shows. “Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis” was published in the journal…

Men who are active smokers and experience faster respiratory decline when diagnosed with idiopathic pulmonary fibrosis (IPF) are at greater risk to develop lung cancer, according to a study. Clinicians should be aware of this risk pattern in order to detect and treat lung cancer early in IPF patients, as…

Low body mass index (BMI) is a risk factor for nausea and diarrhea as side effects of Ofev (nintedanib) treatment in patients with idiopathic pulmonary fibrosis (IPF), a study has found. These results also suggest that lower performance status and a full starting dosage are risk factors…

Taking Esbriet (pirfenidone) to manage idiopathic pulmonary fibrosis (IPF) does not increase the risk of heart problems or interfere with commonly used cardiovascular medications, an analysis found. Results of the analysis were published in the journal Advances In Therapy in an article titled, “Cardiovascular Risks,…

When idiopathic pulmonary fibrosis (IPF) runs in families, it tends to begin earlier in life and be more severe, a recent study reported. The study,”Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF),” was published in the journal BMC Pulmonary Medicine. As its name…